Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.
Solidifying the Synergistic Activity of Toripalimab Plus Chemotherapy in Nasopharyngeal Carcinoma
Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.
Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5